Visine (Tetryzoline)

Quick links

Choose a section

Quick links to important sections

Advertisements

Visine (Tetryzoline)

Selected form

Advertisements
Advertisements

Overview of Visine (Tetryzoline)

What is Visine (Tetryzoline)? Defining the Drug

Property Description
Active Ingredient Tetryzoline Hydrochloride (Tetryzoline cdot HCl)
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Sympathomimetic Agent; Vasoconstrictor
Common Use Temporary relief of eye redness and minor irritation
Origin Synthetic

Visine is a widely recognized over-the-counter (OTC) eye drop solution used primarily for the temporary relief of eye redness (ocular hyperemia). Its active ingredient is Tetryzoline Hydrochloride (INN: International Nonproprietary Name), a compound that has been in medical use since the late 1950s, establishing it as a clinically recognized ophthalmic decongestant.

The product is formulated as a sterile, clear liquid solution for topical administration directly into the eye, providing rapid, localized action. Tetryzoline functions as a decongestant used to relieve redness, burning, and irritation caused by various environmental factors.


What is the Tetryzoline Pharmacological Class and Composition?

Tetryzoline is pharmacologically classified as an alpha-agonist, belonging to the group of sympathomimetic agents and specifically functioning as a potent vasoconstrictor. This mechanism of action is supported by pharmacological data that confirm its ability to selectively target and constrict blood vessels in the conjunctiva. The active ingredient itself is synthetic in origin.

The solution includes the Tetryzoline API along with inactive ingredients such as buffers and preservatives that maintain the drug's stability and safe delivery to the eye surface.


What is Visine (Tetryzoline) Used For?

The general therapeutic purpose of Visine is to provide symptomatic relief from mild, non-infectious eye irritation. The solution is indicated for the relief of redness and discomfort caused by common environmental triggers such as smoke, dust, pollen, or general eye strain.

Visine acts as a temporary reliever only. It is not designed to treat underlying eye diseases, infections, or chronic conditions, which require professional medical attention.

Regulatory References

  1. NIH MedlinePlus
Advertisements

What side effects are possible with Visine (Tetryzoline)?

Possible side effects and safety information

The safety profile of Tetryzoline ophthalmic solution is categorized by official regulatory documents based on the type and frequency of potential effects, primarily separating local effects from systemic concerns.

Officially Documented Adverse Reactions

The most commonly listed adverse reactions are localized to the eye. These often include mild burning or stinging and eye irritation. A temporary enlargement of the pupils (mydriasis) and blurred vision are also documented ocular effects. Systemic reactions, although generally less frequent, may arise from absorption and include manifestations such as headache, nervousness, dizziness, nausea, palpitations, and tachycardia (fast heartbeat).

Time-Related and Serious Safety Concerns

A specific, time-related safety pattern is documented as rebound hyperemia, where prolonged frequent use (overuse) of the drops is associated with a worsening of eye redness. Serious adverse reactions relate primarily to systemic absorption. Systemic effects like hypertension and arrhythmia are listed as potential severe consequences of absorption, and accidental ingestion, particularly by children, is associated with a risk of severe poisoning, leading to profound CNS depression and life-threatening symptoms.

Population-Specific Safety Considerations

Official labeling includes explicit safety considerations for certain populations. The drug is not generally recommended for use during pregnancy. Caution is advised for use in patients with pre-existing conditions that may be aggravated by sympathomimetic agents, including narrow-angle glaucoma, severe cardiovascular disease, hypertension, diabetes mellitus, and hyperthyroidism. Systemic side effects, such as tachycardia, are noted to occur particularly in small children. The medicine is contraindicated in individuals with known hypersensitivity or those taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Help

Overdose from Tetryzoline (the active ingredient in Visine) is primarily a risk following accidental ingestion, particularly in children. Because this drug is a potent vasoconstrictor, systemic absorption can lead to serious toxicity.

Documented Overdose Presentations

Officially documented clinical signs of systemic overdose include significant Central Nervous System (CNS) depression (e.g., marked drowsiness, lethargy, or coma) and severe cardiovascular effects. These effects often present as a slow heart rate (bradycardia), fluctuation between high and dangerously low blood pressure (hypotension), and changes in breathing, including potentially life-threatening apnea (cessation of breathing).

Required Emergency Action

Immediate medical attention is required if Tetryzoline eye drops or nasal spray are swallowed. The accidental ingestion of even a small amount (1–2 mL) is explicitly documented in regulatory materials as posing a life-threatening risk, especially to young children. Individuals should immediately contact a Poison Control Center and be prepared to provide information on the product, the amount ingested, and the time of exposure.

Treatment is supportive and focuses on managing symptoms and continuously monitoring vital signs, including heart function (ECG), blood pressure, and respiratory status, often requiring continuous observation in a hospital setting.

Advertisements

Therapeutic Uses of Visine (Tetryzoline)

What Visine (Tetryzoline) Treats: Main Uses and Benefits

Tetryzoline is commonly used to help with symptoms related to irritative states and is considered relevant when supportive symptom management is appropriate, particularly in situations where individuals experience these types of manifestations.

Relief for Visible Redness and Environmental Discomfort

The medication is relevant across domains where additional symptomatic support is needed for ocular hyperemia (bloodshot appearance), eye burning, stinging, and general irritation. The medication is applied in addressing symptoms that may become more disruptive. The medication may offer aesthetic and visual relief, and supports general well-being during symptomatic phases. It is commonly used across conditions presenting with acute or disruptive episodes linked to exposure from sources such as smoke, dust, wind, or swimming. It is relevant when short-term symptomatic assistance is needed during phases when symptoms become more noticeable, and may assist with maintaining functional stability.


Quick Fact: Relief for Ocular Redness
Tetryzoline is applied in addressing symptom clusters associated with minor, acute eye irritation, which may contribute to easing the overall symptom load.

Regulatory References

  1. DailyMed (NIH National Library of Medicine) overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Visine (Tetryzoline)?

Official regulatory information strictly defines the eligible populations for Tetryzoline ophthalmic solution.

Contraindicated Populations (Absolute Prohibitions)

Contraindication Status
Narrow-Angle Glaucoma Contraindicated
Known Hypersensitivity to Tetryzoline or formulation ingredients Contraindicated
Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) Contraindicated

Age and Condition-Based Restrictions

Tetryzoline is approved for use in adults and children 6 years of age and older. Safety and efficacy are not established for children under 6 years of age, and a doctor must be consulted for use in this group.

Use requires caution and professional consultation for patients with pre-existing conditions such as hypertension, cardiovascular disease, diabetes mellitus, hyperthyroidism, or conditions that may cause urinary retention (e.g., prostatic hypertrophy).

Individuals who are pregnant or breast-feeding are officially directed to ask a health professional before use, as use is generally not recommended unless considered essential. Data for dose adjustments in cases of hepatic or renal impairment are not available.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Tetryzoline (Visine) is defined by its sympathomimetic classification, leading to specific pharmacodynamic interaction risks.

The most critical interaction is the Contraindicated Combination with Monoamine Oxidase Inhibitors (MAOIs). Co-administration is formally restricted due to the risk of pharmacodynamic potentiation, which can result in a severe systemic hypertensive crisis. Clinically significant caution is also required for the use of Tetryzoline with Tricyclic Antidepressants (TCAs) and the specific medicine Guanethidine due to the potential for increased blood pressure and heart rate.

These risks stem from the product's classification as a vasoconstrictor.

The interaction profile includes mandatory Administration-Timing Constraints. When using Tetryzoline with other topical eye medications, a separation interval of at least 5 minutes must be maintained to prevent drug washout. Furthermore, soft contact lenses must be removed before use, with re-insertion restricted for 10 to 15 minutes due to the interaction between the product’s preservative and the lens material.

Official regulatory summaries confirm that no metabolic (CYP enzyme) or transporter-mediated interactions are explicitly documented. The labels also explicitly state there are no known interactions with food, alcohol, or herbal products for the ophthalmic formulation.

Advertisements

Mechanism of Action

Selective alpha1 Agonism and Vascular Contraction

Tetryzoline's action begins with the selective activation (agonism) of alpha-1 (alpha1) adrenergic receptors found on the smooth muscle lining the blood vessels of the conjunctiva. This binding initiates an intracellular calcium signaling cascade that directly results in vascular smooth muscle contraction, which is the fundamental mechanism that governs the resulting physiological effect.


Modulation of Local Vascular Tone

The resulting muscle contraction leads to vasoconstriction, or the physical narrowing of the superficial ocular blood vessels. This adjustment of local vascular tone is the direct physiological process that limits the blood flow and tissue engorgement, defining the resulting physiological change. This mechanism is primarily peripheral, focused solely on regulating the contractile state of the blood vessel walls.


Constraints Due to Receptor Dynamics

The continuous nature of this alpha1 agonism can engage the body's homeostatic feedback loop, leading to two key constraints: tachyphylaxis (a rapid decrease in response due to receptor desensitization) and the subsequent potential for rebound hyperemia (increased vascular engorgement upon cessation), where the system compensates for the drug's action by upregulating opposing vasodilator signals.

Advertisements

Dosage and Administration Information

How to Use Tetryzoline Ophthalmic Solution

The following outlines the standard administration of Tetryzoline 0.05% ophthalmic solution for temporary use.


Administration Details

Scope Instruction
Route of Administration Ophthalmic (drops instilled in the eye).
Dosing Schedule Instill 1 or 2 drops in the affected eye(s) up to 4 times a day.
Max. Self-Medication Duration 72 hours (3 days). Discontinue use if condition persists or worsens after this period.
Age-Group Rules Adults and children 6 years of age and over: Use standard dose. Children under 6: Consult a doctor. Children under 2: Do not use.
Missed Dose Since the drops are used as needed (PRN), no specific recovery is documented. If a dose is missed on a regular schedule, skip it if it is nearly time for the next dose; do not double the dose.

Procedural Steps

  1. Wash hands thoroughly before handling the product.
  2. Remove contact lenses before use. Wait at least 15 minutes before reinserting them.
  3. Check the solution: Do not use the solution if it has changed color or become cloudy.
  4. Avoid contamination: Do not touch the tip of the container to the eye, eyelid, or any other surface.
  5. Administer the drops: Instill the designated 1 or 2 drops into the affected eye(s).
  6. Replace the cap securely after each use.

These instructions define the manner of use and frequency for proper administration, limiting the usage duration for temporary relief.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Visine (Tetryzoline)


Evidence Supporting Temporary Relief of Ocular Redness

The evidence base for Tetryzoline supports its regulatory status as Generally Recognized as Safe and Effective (GRASE) for its temporary indication. This status is primarily founded on a comprehensive review of scientific literature and long-standing experience summarized within regulatory documents, such as the U.S. Food and Drug Administration's (FDA) over-the-counter (OTC) monographs.

Research primarily involved short-term Randomized Controlled Trials (RCTs) that explored how symptoms evolved in the observed populations for this indication. These studies compared the eye drop solution against an inactive placebo. Studies monitored outcomes linked to irritative states, and research was conducted to examine changes in the visible redness of the conjunctiva. Additionally, studies explored patient-reported outcomes describing perceived discomfort, such as burning and stinging.

Findings describe patterns observed in the studies related to the immediate, acute effect on the visible redness of the conjunctiva that was examined. The evidence contributes to understanding the short-term symptom patterns that occur during episodes of heightened symptom activity.

Duration and Follow-up in Clinical Studies

The evidence base is generally characterized by limited follow-up durations. The studies monitored responses over defined time intervals immediately following administration to assess the duration of the observed effect. Research describes patterns related to short-term changes measured during the study period. The regulatory framework defines the scope of this ingredient as temporary, and no authorization exists for continuous or chronic administration.

What Remains Uncertain About Tetryzoline Research

While the immediate, short-term effect on visible redness was observed in some studies, evidence is limited regarding data for long-term or chronic use. The product is not intended for continuous use, and the long-term effects are not fully established. Furthermore, scientific literature notes that frequent or prolonged use was associated with certain patterns of diminished response over time. Findings indicate a documented risk of a potential phenomenon known as rebound hyperemia, where the initial symptom of redness was observed to return and may appear more intense upon discontinuation. This evidence provides context, highlighting what has been studied in the context of temporary use, and what is still uncertain regarding outcomes following extended use.

Key Studies & References Tetryzoline Ophthalmic Solution: Drug Information (NIH MedlinePlus)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Visine (Tetryzoline) (FAQ)

Q: How long do the effects of Visine usually last?

The effect of Tetryzoline is temporary relief of eye redness. According to official guidelines that permit dosing up to four times daily, the intended duration of the visual effect is typically several hours between applications. Clinical information indicates the duration of the effect is generally a few hours.

Q: Can Visine be used with artificial tears?

Official administration guidelines state that Tetryzoline eye drops must be separated by at least 5 minutes from any other topical eye medications, which includes lubricating drops or artificial tears. This measure is required to ensure the second drop does not wash out the first, potentially reducing the intended effect.

Q: What kind of eye conditions should be discussed with a healthcare provider before using Visine?

Regulatory documents specify certain symptoms that require consulting a health professional. Regulatory labels require the user to discontinue use and consult a health professional if eye pain, changes in vision, or if the redness or irritation continues or worsens after 72 hours of self-use. These signs may indicate a more serious underlying eye problem.

Q: Does Visine have any ingredients that can stain clothing or contact lenses?

The preservative commonly used in many Tetryzoline eye drop formulations, such as benzalkonium chloride, has been noted to absorb into soft contact lenses. This absorption can lead to irritation or potential discoloration of the lens material. No official warnings regarding clothing stains are documented.

Q: What are the main inactive ingredients in Visine?

Tetryzoline is the active ingredient, but the solution also contains other components necessary for stability and safe delivery. Official regulatory labels typically list inactive ingredients such as the preservative benzalkonium chloride, along with buffers like boric acid and sodium chloride.

Q: What if the Visine bottle was left in a hot car?

Official storage requirements state that the product must be kept at a controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Exposure to high heat, such as that inside a hot vehicle, may affect the product's quality or stability, and adherence to the temperature range is required to maintain product stability.

Q: Is Visine the same as other allergy eye drops?

Visine’s active ingredient, Tetryzoline, is classified as a vasoconstrictor (a medicine that narrows blood vessels) and reduces redness by this action. This mechanism is different from that of antihistamine eye drops, which are often used for allergies and work by blocking the body's histamine response.

Q: How quickly does Visine start working?

Clinical and pharmacological reviews indicate that Tetryzoline typically has a rapid onset of action. The medicine begins working quickly after application, often providing a perceived effect within minutes.

Q: What is the difference between Visine and lubricating eye drops?

Tetryzoline is a decongestant whose primary function is to physically narrow blood vessels (vasoconstriction) to reduce visible redness. In contrast, lubricating eye drops, or artificial tears, are used primarily to supplement moisture on the eye surface to relieve symptoms of dryness and general irritation.

Q: Can using Visine make my eyes feel dry later?

Regulatory safety profiles for topical Tetryzoline indicate that dryness of the eye is listed as a potential, though usually mild, side effect. Other common local effects include temporary stinging or irritation immediately after use.

Q: Do other active ingredients work similarly to Tetryzoline?

Yes, Tetryzoline is one of several alpha-adrenergic agonists used as over-the-counter (OTC) ocular decongestants. Official reviews note that other ingredients like naphazoline or brimonidine operate similarly by stimulating these receptors to achieve the same effect of vasoconstriction and reducing redness.

Q: What is the shelf life of an unopened bottle of Visine?

Official documents for some formulations provide the authorized shelf life of the unopened product when stored correctly. This period is typically noted as 24 months from the manufacturing date.

Q: Can I use Visine for eyes that are red from lack of sleep?

Tetryzoline is indicated for the temporary relief of redness and minor irritation caused by various common environmental factors, including general eye strain. Redness associated with lack of sleep is typically considered a form of general eye strain.

Q: Does Tetryzoline interact with common over-the-counter pain relievers?

The regulatory interaction labels for Tetryzoline focus primarily on contraindications with prescription medicines, such as MAOIs. Official documents do not list known interactions between the eye drop formulation and common over-the-counter pain relievers.

Q: Can I use Visine for eyes that are red from swimming pool chlorine?

The product is officially indicated for relieving redness and minor irritation caused by various common environmental factors. Chemical irritants like swimming pool chlorine are generally considered to fall under the category of minor eye irritation.

Q: Do I need to shake the Visine bottle before using it?

The official procedural steps provided in regulatory labeling for administering the eye drops do not include an instruction to shake the bottle before use. The instructions emphasize washing hands and checking the solution’s clarity.

Advertisements

How should Visine (Tetryzoline) be stored and disposed of?

Storage and Disposal Requirements

Tetryzoline ophthalmic solution must be stored according to specific regulatory conditions to maintain stability and prevent contamination.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, typically 15 to 30 C (59 to 86 F). Do not freeze.
Container Integrity Replace the cap after each use and do not touch the container tip to any surface.
Stability Check Do not use the solution if it changes color or becomes cloudy. Some formulations should be discarded 28 days after opening.

Safety and Disposal

Official labeling mandates that the product must be kept out of reach of children. If accidental ingestion occurs, medical help or a Poison Control Center must be contacted immediately. Unused or expired product should be disposed of in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Visine (Tetryzoline) found in:

A-Z Index: